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Estrogens regulate interleukin-6 (IL6) expression. Polymorphisms in estrogen receptor alpha (ESR1) and
in IL6 genes have been associated with BMD in post-menopausal women. Whether genetic variation in
ESR1 and IL6 plays a role on bone mass acquisition however remains unknown. We examined the asso-
ciation of ESR1-XbaI and IL6 -174 G>C polymorphisms with BMD and their interaction with calcium in-
take in 139 girls and 232 boys who received calcium supplements (800 mg/d) or placebo for 1 yr. BMD at
lumbar spine (LS), total hip (TH), femoral neck (FN), ultra distal (UR) and total radius (TR) was evaluated
by DXA at baseline (mean age 7.6±0.4 yrs) and after 1 and 2 yrs (age 9.9±0.5 yrs). Genotypes distribu-
tion was similar in both genders. ESR1 genotypes were associated with baseline BMD at most skeletal
sites (p=0.01-0.06), with a borderline interaction with sex (P•0.09). Indeed, xx females had 2-6% higher
BMD compared to Xx and/or XX (LS p=0.04 and p=0.03; FN p=0.004 and p=0.05; TH p=0.009 and ns;
TR p=0.005 and ns at baseline and after 2 yrs, respectively), whereas males did not. ESR1 genotypes
were not associated with BMD gain in absence of calcium supplements, but a significant interaction with
calcium supplements occurred on hip (P=0.03). Indeed, calcium supplements increased FN and TH BMD
gain 2-3x above placebo among XX, but not among carriers of the x allele. At baseline, IL6 -174 geno-
types were associated with BMD at LS (+4% in GG compared to CC and GC, p=0.001), and without evi-
dence of interaction with sex. After two years, this association became weaker (p=0.05), since GG from
both genders had a 26% lower LS BMD gain during yr 2 in absence of calcium supplements (p=0.01 vs
CC and GC, adjusted for age, pubertal stage). Calcium supplements significantly increased TR and UR
BMD gain in males and females (p=0.006 and p=0.05, respectively), without evidence of interaction with
IL6 genotypes. In conclusions, ESR1-XbaI and IL6 promoter –174G>C polymorphisms are associated
with BMD and BMD gain in prepubertal children. Whereas IL6 genetic variation appears to modulate bone
mass acquisition at LS irrespective of sex and calcium intake, the broad influence of ESR1 genotypes on
BMD was more prominent in females and may depend on the level of calcium intake. 
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